EcoDrugPlus

60s Ribosomal Protein L6-Like

Ensembl ID : ENSSTUG00000048032
Gene Symbol: LOC115200292
3 Cross references
481 Possible Orthologues:

60s Ribosomal Protein L6-Like

Ensembl ID : ENSSTUG00000038540
Gene Symbol: LOC115164356
3 Cross references
481 Possible Orthologues:

60s Ribosomal Protein L7-Like

Ensembl ID : ENSSTUG00000043928
Gene Symbol: LOC115195327
3 Cross references
487 Possible Orthologues:

60s Ribosomal Protein L7-Like

Ensembl ID : ENSSTUG00000020631
Gene Symbol: LOC115149080
3 Cross references
487 Possible Orthologues:

60s Ribosomal Protein L8

Ensembl ID : ENSSTUG00000006146
Gene Symbol: LOC115161301
3 Cross references
252 Possible Orthologues:

60s Ribosomal Protein L8-Like

Ensembl ID : ENSSTUG00000024568
Gene Symbol: LOC115155911
3 Cross references
252 Possible Orthologues:

72 Kda Type Iv Collagenase-Like

Ensembl ID : ENSSTUG00000040360
Gene Symbol: LOC115203309
3 Cross references
200 Possible Orthologues:

72 Kda Type Iv Collagenase-Like

Ensembl ID : ENSSTUG00000049696
Gene Symbol: LOC115167017
3 Cross references
198 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSTUG00000008699
Gene Symbol: ABL1
3 Cross references
196 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSTUG00000018521
Gene Symbol: ABL1
3 Cross references
196 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSTUG00000028571
Gene Symbol: ADAM17
3 Cross references
204 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSTUG00000049899
Gene Symbol: ADAM17
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).